Stockscreener 앱 받기
10.15
2.31%
-0.24
시간 외 거래:
10.15
전일 마감가:
$10.39
열려 있는:
$10.725
하루 거래량:
1.19M
Relative Volume:
0.71
시가총액:
$901.06M
수익:
$71.64M
순이익/손실:
$-294.57M
주가수익비율:
-3.0317
EPS:
-3.348
순현금흐름:
$-84.46M
1주 성능:
-4.96%
1개월 성능:
-6.88%
6개월 성능:
+19.83%
1년 성능:
+62.92%
1일 변동 폭
$10.13
$10.77
1주일 범위
$10.13
$10.92
52주 변동 폭
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
10.15 | 922.37M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Lake Street | Buy |
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Kura Oncology Reports 50% Response Rate in RCC Combination Study - Yahoo Finance
KURA Shows Promising Results in Phase 1a Kidney Cancer Trial - GuruFocus
Kura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma - Quiver Quantitative
Kura's Drug Combo Shows 13-Month Median Without Progression - Stock Titan
Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kura Oncology Inc (KURA) Institutional Confidence - TradingKey
Kura Oncology Inc (KURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Why Did KURA Stock Jump 13% In Pre-Market Today? - Stocktwits
Kura Oncology Inc (KURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kura Oncology Inc (KURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
KURA|Kura Oncology Inc|Price:10.499|Chg%:+0.109 - TradingKey
KURA|Kura Oncology Inc|Price:10.390|Chg%:-0.060 - TradingKey
KURA|Kura Oncology Inc|Price:10.690|Chg%:+0.300 - TradingKey
Enterprise value to EBIT forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology, Inc. (KURA) Stock Analysis: Exploring a Promising 198% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Bank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA) - The Globe and Mail
(KURA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Barclays Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Is Kura Oncology (KURA) Undervalued On New FIT 001 Trial Data? - Yahoo Finance
Is Kura Oncology (KURA) Turning Darlifarnib Into a Foundational Precision Combo Platform? - Sahm
Enterprise value to revenue forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology presents new data supporting darl... - Pluang
Kura Oncology to Present First Long-Term Follow-Up Data - GlobeNewswire
Long-term kidney cancer data from Kura's drug due July 24 - Stock Titan
Enterprise value to EBITDA forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Price to earnings forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Price to sales forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Price to book forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win (NASDAQ:KURA) - Seeking Alpha
Kura Oncology (KURA) Jefferies London Healthcare Conference 2025 Summary - Quartr
Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story? - Yahoo Finance
Kura Oncology outlines targeted cancer pipeline as investors watch clinical milestones - Ad-hoc-news.de
Kura Oncology (KURA) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary - Quartr
Kura Oncology (KURA) Gains Nearly 3% as Shares Test Key Resistance ZoneAnalyst Downgrade Signals - dars.gov.et
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Kura Oncology reports $5.8 million revenue in Q1 2026 - scanx.trade
Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2500 Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2000 Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 3000 Growth Benchmark - marketscreener.com
Kura Oncology, Inc. Actuals & Estimates (NASDAQ:KURA) - TradingView
Kura Oncology, Inc. Actuals & Estimates (HAM:KUR) - TradingView
Kura Oncology, Inc. liabilities 2021-2025 - Statista
Kura Oncology, Inc. Actuals & Estimates (DUS:KUR) - TradingView
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):